spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  dronedarone 

 HSMN NewsFeed - 26 Jul 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Nov 2012
URGENT NOTICE -- DRUG RECALL: Boehringer Ingelheim Pharmaceuticals, Inc. Initiates a Voluntary Recall of a Single Manufacturing Lot of Pradaxa(R) (dabigatran etexilate mesylate) Capsules 75mg in the U.S. and Puerto Rico
Biopharmaceuticals Cardiology Product Recall
 HSMN NewsFeed - 30 Nov 2009
sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 28 Sep 2009
sanofi-aventis: Multaq(R) (dronedarone) Recommended for Approval in the European Union
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 28 Jul 2009
MULTAQ(R) (dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Jul 2009
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 18 Mar 2009
FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 11 Feb 2009
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2008
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 Aug 2008
Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 15 May 2008
Landmark ATHENA Study Findings With Multaq(R)(dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Sep 2007
The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
dronedarone
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.